0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Ideas and Opinions |

Fixed-Dose Combinations of Antituberculous Medications To Prevent Drug Resistance

Thomas Moulding, MD; Asim K. Dutt, MD; and Lee B. Reichman, MD, MPH
[+] Article and Author Information

From Harbor-University of California, Los Angeles, Medical Center, Torrance, California. Alvin C. York Veterans Administration Medical Center, Murfreesboro, Tennessee. New Jersey Medical School, Newark, New Jersey. Requests for Reprints: Thomas S. Moulding, MD, Division of Respiratory and Critical Care Physiology and Medicine, Harbor-University of California, Los Angeles, Medical Center, Torrance, CA 90501. Grant Support: By Cooperative Agreement 200-93-0636 from the Centers for Disease Control and Prevention; Tuberculosis Career Academic Award K07-h103015-01 from the Division of Lung Disease of the National Heart, Lung, and Blood Institute; and Research Consortium Grant 200-93-0690 from the Centers for Disease Control and Prevention.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1995;122(12):951-954. doi:10.7326/0003-4819-122-12-199506150-00010
Text Size: A A A

The treatment of tuberculosis requires at least two drugs to retard the development of drug resistance. Unfortunately, patients may take only one drug (monotherapy) when more than one is prescribed. Fixed-dose combinations with two or more antituberculous drugs in one capsule or tablet are available to prevent this. In the United States, these drugs are Rifamate (Marion Merrell Dow), which contains isoniazid plus rifampin, and Rifater (Marion Merrell Dow), which contains isoniazid plus rifampin and pyrazinamide. Because these preparations make monotherapy impossible, they are clearly preferable to individual drugs. In the United States in 1993, however, only 15% to 18% of rifampin was sold in the form of fixed-dose combinations. To correct this deficiency, fixed-dose combinations should be widely promoted and accepted as a primary way to prevent drug-resistant tuberculosis. There are two caveats regarding these preparations. First, many fixed-dose combinations, especially those in developing countries, achieve inadequate blood levels of one or more of the component drugs, especially rifampin. Our recommendations apply only to preparations with proven bioavailability. Second, because the name Rifamate is similar to the name rifampin, mistakes in prescribing and dispensing can result in the patient receiving rifampin alone when Rifamate is intended. A name change from Rifamate to a highly distinctive name such as Rif-Isoniazid is needed to prevent such occurrences.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Journal Club
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)